February 26, 2018 / 12:07 PM / 3 months ago

BRIEF-Summit Therapeutics ‍Announces Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation In Phase 2 Clinical Trial

Feb 26 (Reuters) - Summit Therapeutics Plc:

* ‍ANNOUNCES NEW ANALYSIS SHOWING EZUTROMID SIGNIFICANTLY REDUCED MUSCLE INFLAMMATION IN PHASE 2 CLINICAL TRIAL IN DMD​

* ‍MRS-T2 DATA PROVIDE EVIDENCE OF EARLY IMPACT OF EZUTROMID ON DOWNSTREAM MUSCLE HEALTH​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below